{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["3(1)"],"submitter":["Dunham N"],"pubmed_abstract":["Relapsed acute myeloid leukemia (relAML) remains a clinical challenge. We have shown that epigenetic heterogeneity may contribute to transcriptional dysregulation and disease progression in AML, but the specific aberrant transcriptional programs have not been identified. We analyzed molecular profiles from patient-matched diagnostic and relapse AML specimens. A subset of differentially expressed genes (DEG) that were disparate in direction of expression change identified 2 patient subtypes. We predicted that transcriptional regulators (TR) might regulate the expression patterns observed. The expression patterns of the top TR predicted for the disparate genes associated with clinical outcomes. The top TR predicted for the disparate DEG and DEG identified in a patient-derived xenograft model"],"journal":["Blood neoplasia"],"pagination":["100186"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12835595"],"repository":["biostudies-literature"],"pubmed_title":["The LMO2-LDB1-TAL1 complex regulates transcription networks in acute myeloid leukemia."],"pmcid":["PMC12835595"],"pubmed_authors":["Neelamraju Y","Sheynkman G","Gandara JA","Melnick AM","Neuberg DS","Rapaport F","Guo Y","Patnaik I","Garrett-Bakelman FE","Levine RL","Bullinger L","Becker MW","Fan H","Sheridan C","Dillon R","Wang Z","Layer JH","Dunham N","Mason CE","Abdelmalak FA","Zumbo P","Paudel BB","Meydan C","Bekiranov S","Prajapati S","Carroll MP","Dave UP","McDonald WH","Maier B","D'Andrea RJ","Zang C","Hardwick J","Lee T"],"additional_accession":[]},"is_claimable":false,"name":"The LMO2-LDB1-TAL1 complex regulates transcription networks in acute myeloid leukemia.","description":"Relapsed acute myeloid leukemia (relAML) remains a clinical challenge. We have shown that epigenetic heterogeneity may contribute to transcriptional dysregulation and disease progression in AML, but the specific aberrant transcriptional programs have not been identified. We analyzed molecular profiles from patient-matched diagnostic and relapse AML specimens. A subset of differentially expressed genes (DEG) that were disparate in direction of expression change identified 2 patient subtypes. We predicted that transcriptional regulators (TR) might regulate the expression patterns observed. The expression patterns of the top TR predicted for the disparate genes associated with clinical outcomes. The top TR predicted for the disparate DEG and DEG identified in a patient-derived xenograft model","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-06-16T03:07:59.96Z","creation":"2026-06-16T03:06:37.843Z"},"accession":"S-EPMC12835595","cross_references":{"pubmed":["41608320"],"doi":["10.1016/j.bneo.2025.100186"]}}